Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Market Cap	$131.67M	P/E Ratio	N/A
52W High	$4.98	52W Low	$2.07
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	51.9%
Overall Score	59	Value Score	40
Quality Score	47	Technical Score	91

EPS Current Est	$-0.35	EPS Next Est	$-0.38
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANIX	$3.58	-25.42%	2.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANIX	$3.58	-25.4%	2.15M
3
4
5
6

ANIX

ANIX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Anixa Biosciences Inc. Data in Excel

Get Anixa Biosciences Inc. Data in Excel